Hepatitis B vaccine: Phase IIb/III started

Abivax began an open-label, international Phase IIb/III trial to compare 10 doses of subcutaneous ABX203 over 24 weeks plus nucleoside or nucleotide analog therapy for 48 weeks vs. nucleoside or nucle...